Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Rapport Therapeutics Shares Rise 7% After Positive Phase 2 Bipolar Mania Results for RAP-219

Rapport Therapeutics Announces Positive Phase 2 Bipolar Mania Results for RAP-219

+7.24% $28.60 when we broke this story → $30.67 at 10:17 AM ET, 20 Oct 2026

Rapport Therapeutics has successfully met the primary endpoint in a Phase 2 clinical trial evaluating RAP-219 for the treatment of acute bipolar mania. The candidate demonstrated statistically significant improvements in manic symptoms compared to placebo while maintaining a clean safety profile with no serious adverse events reported.

Engineering, computer, office, laboratory. Stock photo illustrating Rapport Therapeutics' other story.
Rapport Therapeutics, Inc. · Healthcare · Photo: This_is_Engineering / Pixabay

Key highlights

  • RAP-219 achieved a statistically significant 3.1-point placebo-adjusted improvement in YMRS total score at Week 3
  • Trial reported a 15.4-point mean reduction from baseline in the RAP-219 treatment arm
  • Secondary endpoint CGI-BP Severity of Mania score improved by 0.4 points over placebo
  • Candidate was well-tolerated with no severe treatment-emergent or serious adverse events observed
  • Company expects to initiate two Phase 3 clinical trials in bipolar mania in the second half of 2027

Phase 2 Clinical Performance

Rapport Therapeutics reported that its Phase 2 trial for RAP-219 in adults with acute bipolar I mania met its primary endpoint. The randomized, double-blind study involved 253 patients and measured results using the Young Mania Rating Scale (YMRS) over a three-week treatment period. At the end of the study, RAP-219 achieved a 3.1-point placebo-adjusted improvement in the total YMRS score. Patients treated with the drug saw a 15.4-point reduction from baseline. The company also noted improvements across all 11 YMRS items, including irritability, thought content, and disruptive-aggressive behavior reaching nominal significance.

Strategic Development Roadmap

These results provide clinical proof-of-concept for the novel transmembrane AMPA receptor regulatory protein (TARP) g8-selective mechanism. This approach aims to provide precise neuromodulation, potentially offering a treatment option with fewer side effects than traditional therapies. The success in bipolar mania follows previously reported positive Phase 2a data for focal epilepsy, reinforcing the potential of RAP-219 as a multifaceted neurological treatment. Rapport intends to initiate Phase 3 clinical trials for the bipolar mania indication in the second half of 2027, following further engagement with regulatory authorities and ongoing Phase 3 programs in epilepsy.

Financial and Market Context

  • Maintained $436.1 million in cash and short-term investments as of mid-2026
  • Operations fully funded through the second half of 2029 according to current guidance
  • Previously established a $328 million licensing agreement with Tenacia Biotechnology for Greater China
  • Ongoing Phase 3 FOCUS trials in focal onset seizures with patient recruitment active in multiple regions
  • Stock recently traded near oversold territory with a 14-day relative strength index of 29.9
Rapport Therapeutics, Inc. share price · last month
Line chart of Rapport Therapeutics, Inc.'s share price over the last month, from $28.60 on 19 Oct → $24.82 on 16 Nov; our story on 20 Oct at $28.60.

Down 13.2% since our story on 20 Oct: $28.60 when we broke it → $24.82 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$28.60
20 Oct$29.37
21 Oct$25.06
22 Oct$26.53
23 Oct$25.93
26 Oct$25.33
27 Oct$27.54
28 Oct$22.50
29 Oct$24.21
30 Oct$25.05
2 Nov$25.13
3 Nov$25.44
4 Nov$25.93
5 Nov$23.72
6 Nov$24.44
9 Nov$26.07
10 Nov$25.96
11 Nov$27.02
12 Nov$25.85
13 Nov$26.15
16 Nov$24.82

Management on Mechanism Innovation

“For people with bipolar disorder, the challenge isn’t just finding a treatment that’s efficacious. It’s finding one they can tolerate and stay on. Side effects drive discontinuation, and discontinuation drives relapse. RAP-219 has the potential to break that cycle with the first new mechanism of action for bipolar mania in decades.”

Abraham N. Ceesay, CEO, Rapport Therapeutics

Industry Dynamics

The bipolar disorder market is characterized by significant unmet needs, as current standard-of-care treatments often lead to high discontinuation rates due to severe side effects. Relapses are frequently triggered when patients stop medication to avoid these adverse impacts. By developing a drug with a novel mechanism of action that was well-tolerated in Phase 2 trials, Rapport aims to address the cyclical nature of the condition. The global market for bipolar disorder therapeutics represents a multi-billion dollar opportunity, particularly for treatments that can demonstrate long-term patient adherence through better tolerability profiles.

Earlier announcements by Rapport Therapeutics, Inc.
DateAnnouncementAmount
05 Aug 2026Second quarter 2026 financial results and initiation of Phase 3 FOCUS 1 and FOCUS 2 trials in focal onset seizuresSource: SEC filing–
07 May 2026First quarter 2026 financial results and corporate business updateSource: investors.rapportrx.com–
09 Mar 2026Strategic collaboration and license agreement with Tenacia Biotechnology for RAP-219 in Greater ChinaSource: investors.rapportrx.com$328.0 Million
09 Sep 2025Pricing of public offering of 9,615,385 shares of common stock at $26.00 per shareSource: investors.rapportrx.com$250.0 Million
08 Sep 2025Positive topline results from Phase 2a clinical trial of RAP-219 in focal onset seizuresSource: investors.rapportrx.com–

Management commentary

“Together with our positive Phase 2 focal epilepsy data, these results strengthen RAP-219’s profile across each indication we are pursuing and show it delivering on its potential as a pipeline-in-a-product with two indications that both represent multibillion dollar market opportunities.”

Abraham N. Ceesay, Chief Executive Officer
Rapport Therapeutics, Inc. · financial snapshot
Share price$28.60
Market cap$1.4B
1-month price change-31.82%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Rapport Therapeutics announcing topline Phase 2 results for RAP-219 in bipolar mania.

Read the filing ↗

Track Rapport Therapeutics, Inc. live

Get the next Rapport Therapeutics, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.